CD8A and neoplasm: The vaccine should (1) result in efficient Ag cross-presentation by DCs, (2) include tumor-specific or tumor-associated Ags that can overcome existing CD8+ T cell tolerance and (3) contain the right adjuvant to support the induction of strong CD8+ T cell responses.